Cipla Gets New Price-Violation Notice From India Regulator
This article was originally published in PharmAsia News
Executive Summary
India's drug-pricing regulator served notice on Cipla for violating the rules in pricing its generic version of the antibiotic ciprofloxacin within the past nine months. At the same time, the Indian Supreme Court is considering another accusation that Cipla overcharged for a range of antibiotics and anti-asthma drugs four years ago. Cipla contends the new notice issued by the National Pharmaceutical Pricing Authority is covered by the pending court case brought by Cipla. Cipla contended in that case that NPPA's penalties were untenable and could not be sustained. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.